Journal of Infection and Chemotherapy

, Volume 4, Issue 3, pp 116–120 | Cite as

Effects of fluoroquinolones on experimental pneumonia caused by penicillin-resistantStreptococcus pneumoniae in mice

  • Sadao Tamada
  • Katsuhisa Nakata
  • Shinsuke Watanabe
  • Yoshihito Niki
  • Toshiharu Matsushima
Original Articles
  • 12 Downloads

Abstract

The in vitro and in vivo activities of several fluoroquinolones, ampicillin and cefteram-pivoxil were investigated against penicillin-resistantStreptococcus pneumoniae (PRSP). The MIC90s of sparfloxacin, levofloxacin, tosufloxacin, AM-1155, ampicillin, and cefteram-pivoxil for 13 PRSP strains were 0.78, 3.13, 0.39, 1.56, 3.13, and 3.13 μg/mL, respectively. An experimental fatal pneumonia was induced by intranasal inoculation of PRSP No. 65 in CBA/J mice. The fluoroquinolones were effective against the experimental pneumonia, but ampicillin and cefteram-pivoxil were not sufficiently effective. The oral 50% effective doses (ED50) of sparfloxacin, levofloxacin, tosufloxacin, and AM-1155 on the experimental pneumonia were 6.09, 49.3, 5.07, and 8.59 mg/kg/dose, respectively, when treatment was initiated 3 hours after infection and were 30.0, >50, 17.7, and 45.9 mg/kg/dose, respectively, when treatment was initiated 24 hours after infection. These results suggest that some fluoroquinolones such as sparfloxacin, tosufloxacin and AM-1155 may be effective in the treatment of pneumonia due to PRSP in humans.

Key Words

fluoroquinolones pneumonia mouse model Streptococcus pneumoniae penicillin resistance 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Arthur LB, Steven DB, William JN. In vitro activities of cefotaxime, ceftriaxone, ceftazidime, cefpirome, and penicillin againstStreptococcus pneumoniae isolates. Antimicrob Agents Chemother 1995;39:2193–2196.Google Scholar
  2. 2.
    Chesney PJ. The escalating problem of antimicrobial resistance onStreptococcus pneumoniae. Am J Dis Child 1992; 146:912–916.PubMedGoogle Scholar
  3. 3.
    Kan KM, Luey KY, Fung SM, Yiu PP, Harden TJ, Cheung MM. Emergence of multiple-antibiotic-resistantStreptococcus pneumoniae in Hong Kong. Antimicrob Agents Chemother 1995;39:2667–2670.Google Scholar
  4. 4.
    Spika SJ, Richard R, Flicklam BD, Margaret JO, Pneumococcal Surveillance Working Group. Antimicrobial resistance ofStreptococcus pneumoniae in the United States, 1979–1987. J Infect Dis 1991;163:1273–1278.PubMedGoogle Scholar
  5. 5.
    Ubukata K, Asahi Y, Okuzumi K, Konno H. Incidence of penicillin-resistantStreptococcus pneumoniae in Japan, 1993–1995. J Infect Chemother 1996;1:177–184.CrossRefGoogle Scholar
  6. 6.
    Konno M. An epidemiological study of penicillin-resistantStreptococcus pneumoniae in Japan. J Jap Assoc Infect Dis 1994;68:1338–1351.Google Scholar
  7. 7.
    Canton E, Peman J, Jimerez MJ, Ramon MS, Gobernado M. In vitro activity of sparfloxacin compared with those of the five other quinolones. Antimicrob Agents Chemother 1992;36:558–565.PubMedGoogle Scholar
  8. 8.
    Girade AE, Girard D, Gootz TD, Faiella JA, Cimochowski CR. In vitro efficacy of trovafloxacin (CP-99219), a new quinolone with extended activities against gram-positive pathogens,Streptococcus pneumoniae, andBacteroides fragilis. Antimicrob Agents Chemother 1995;39:2210–2216.Google Scholar
  9. 9.
    Nakamura S, Minami A, Nakata K, Kurobe N, Kono K, Sakaguchi Y, et al. In vitro and in vivo antibacterial activities of AT-4140, a new broad-spectrum quinolone. Antimicrob Agents Chemother 1989;33:1167–1173.PubMedGoogle Scholar
  10. 10.
    Pankuch GA, Jacobs MR, Appelbaum FC. Activity of CP-99, 219, compared with 6859a, ciprofloxacin, ofloxacin, levofloxacin, lomefloxacin, tosufloxacin, sparfloxacin and grepafloxacin against penicillin-susceptible and-resistant pneumococci. J Antimicrob Chemother 1995;35:230–232.PubMedGoogle Scholar
  11. 11.
    Simizu M. Quinolone antimicrobial agents: their past, present, future. J Infect Chemother 1995;1:16–29.CrossRefGoogle Scholar
  12. 12.
    Azoulay-Dupuis E, Bedos JP, Vallee E, Hardy DJ, Swanson RN, Pocidalo JJ. Antipneumococcal activity of ciprofloxacin, ofloxacin, and temafloxacin in experimental mouse pneumonia model at various stages of the disease. J Infect Dis 1991;163:319–324.PubMedGoogle Scholar
  13. 13.
    Azoulay-Dupuis E, Vallee E, Veber B, Bedos JP, Bauchet J, Pocidalo JJ. In vivo efficacy of a new fluoroquinolone, sparfloxacin against penicillin-susceptible and-resistant and multiresistant strains ofStreptococcus pneumoniae in a mouse model of pneumonia. Antimicrob Agents Chemother 1992;36:2698–2703.PubMedGoogle Scholar
  14. 14.
    Garau J, Vercken JB. Efficacy of sparfloxacin in the treatment of 312 cases of pneumococcal community acquired pneumonia: a pool data analysis. Program and abstracts of the 5th International Symposium on New Quinolones 1994. Singapore, Singapore, August 12–14, 1994 (abstr 40).Google Scholar
  15. 15.
    Niki Y, Tamada S, Nakabayashi M, Soejima R. Sparfloxacin, a new generation fluoroquinolone againstS. pneumoniae respiratory infections. Drugs 1995;49(suppl 2):420–422.PubMedCrossRefGoogle Scholar
  16. 16.
    Takashima K, Tateda K, Matsumoto T, Ito T, Iizawa Y, Yamaguchi K. Experimental respiratory tract infection caused by penicillin-resistantStreptococcus pneumoniae in CBA/J mice. Therapeutic Res (Japan) 1995;16:43–436.Google Scholar
  17. 17.
    Tateda K, Takashima K, Miyazaki H, Ito T, Hatori T, Yamaguchi K. Noncompromised penicillin-resistant pneumococcal pneumonia CBA/J mouse model and comparative efficacious of antibiotics in this model. Antimicrob Agents Chemother 1996;16:433–436.Google Scholar
  18. 18.
    Miller LC, Tainter ML. Estimation of the ED50 and its error by means of logarithmic-probit graph. Proc Soc Exp Biol Med 1944;57:261–264.Google Scholar
  19. 19.
    Litchfield JT, Wilcoxon FA. Simplified method of evaluating dose-effect experiments. J Pharmacol Exp Ther 1949;96:99–113.PubMedGoogle Scholar
  20. 20.
    Austrian R. Pneumococcal pneumonia, diagnosis, epidemiologic, therapeutic and prophylactic consideration. Chest 1986;90:738–743.PubMedGoogle Scholar

Copyright information

© JSC/CLJ 1998

Authors and Affiliations

  • Sadao Tamada
    • 1
  • Katsuhisa Nakata
    • 2
  • Shinsuke Watanabe
    • 1
  • Yoshihito Niki
    • 1
  • Toshiharu Matsushima
    • 1
  1. 1.Division of Respiratory Diseases Department of MedicineKawasaki Medical SchoolOkayamaJapan
  2. 2.Discovery Research Laboratories IIDainippon Pharmaceutical Co. Ltd.OsakaJapan

Personalised recommendations